Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?

Kunos, George; Osei-Hyiaman, Douglas; Bátkai, Sándor; Sharkey, Keith A; Makriyannis, Alexandros

Kunos, George; Osei-Hyiaman, Douglas; Bátkai, Sándor; Sharkey, Keith A; Makriyannis, Alexandros.

Affiliation

Kunos G; Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD 20892, USA. gkunos@mail.nih.gov

Trends Pharmacol Sci ; 30(1): 1-7, 2009 Jan.

Article in En | MEDLINE | ID: mdl-19042036

Subject(s)

Metabolic Diseases/drug therapy; Receptor, Cannabinoid, CB1/antagonists & inhibitors; Animals; Drug Design; Humans; Inflammation/physiopathology; Inflammation/prevention & control; Metabolic Diseases/physiopathology; Metabolic Diseases/prevention & control; Pain/drug therapy; Pain/physiopathology; Pain/prevention & control; Receptor, Cannabinoid, CB1/physiology; Terminology as Topic

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Receptor, Cannabinoid, CB1 / Metabolic Diseases Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Trends Pharmacol Sci Year: 2009 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google